- Home
- DBRG vs BHVN Comparison
DBRG vs BHVN Comparison
Compare DBRG & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- BHVN
- Stock Information
- Founded
- DBRG 1991
- BHVN 2013
- Country
- DBRG United States
- BHVN United States
- Employees
- DBRG N/A
- BHVN N/A
- Industry
- DBRG Real Estate Investment Trusts
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- DBRG Real Estate
- BHVN Health Care
- Exchange
- DBRG Nasdaq
- BHVN Nasdaq
- Market Cap
- DBRG 1.9B
- BHVN 1.9B
- IPO Year
- DBRG 2009
- BHVN 2017
- Fundamental
- Price
- DBRG $11.06
- BHVN $15.13
- Analyst Decision
- DBRG Strong Buy
- BHVN Strong Buy
- Analyst Count
- DBRG 9
- BHVN 14
- Target Price
- DBRG $16.28
- BHVN $59.85
- AVG Volume (30 Days)
- DBRG 3.5M
- BHVN 2.4M
- Earning Date
- DBRG 05-01-2025
- BHVN 05-12-2025
- Dividend Yield
- DBRG 0.36%
- BHVN N/A
- EPS Growth
- DBRG N/A
- BHVN N/A
- EPS
- DBRG 0.32
- BHVN N/A
- Revenue
- DBRG $566,324,000.00
- BHVN N/A
- Revenue This Year
- DBRG N/A
- BHVN N/A
- Revenue Next Year
- DBRG $19.16
- BHVN $65.26
- P/E Ratio
- DBRG $29.57
- BHVN N/A
- Revenue Growth
- DBRG N/A
- BHVN N/A
- 52 Week Low
- DBRG $6.41
- BHVN $14.33
- 52 Week High
- DBRG $17.33
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- DBRG 62.35
- BHVN 31.09
- Support Level
- DBRG $10.66
- BHVN $14.86
- Resistance Level
- DBRG $11.59
- BHVN $15.94
- Average True Range (ATR)
- DBRG 0.59
- BHVN 1.27
- MACD
- DBRG 0.03
- BHVN -0.16
- Stochastic Oscillator
- DBRG 65.20
- BHVN 3.31
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.